Revenue: As of FY2026 Q3, the actual value is USD 657.46 K, missing the estimate of USD 3 M.EPS: As of FY2026 Q3, the actual value is USD -0.6.EBIT: As of FY2026 Q3, the actual value is USD -12.73 M.<h4>Revenue</h4><ul><li>Three Months Ended March 31, 2026:<ul><li>Total Revenue: $657,458, a decrease from $1,422,235 in the prior year. </li><li>Software services revenue: $443,189, down from $1,283,287 in the prior year. </li><li>Software license/software as a service revenue: $209,428, an increase from $138,948 in the prior year. </li><li>Royalty income: $4,841, up from $0 in the prior year. </li></ul></li><li>Nine Months Ended March 31, 2026:<ul><li>Total Revenue: $3,355,808, a decrease from $7,029,538 in the prior year. </li><li>Software services revenue: $2,866,391, down from $6,641,652 in the prior year. </li><li>Software license/software as a service revenue: $461,159, an increase from $387,886 in the prior year. </li><li>Royalty income: $28,258, up from $0 in the prior year. </li></ul></li></ul><h4>Gross Profit</h4><ul><li>Three Months Ended March 31, 2026: $584,099, down from $1,020,026 in the prior year. </li><li>Nine Months Ended March 31, 2026: $2,381,337, down from $4,968,019 in the prior year. </li></ul><h4>Operating Expenses</h4><ul><li>Three Months Ended March 31, 2026:<ul><li>Total operating expenses: $13,289,706, significantly up from $2,604,689 in the prior year, primarily due to goodwill impairment. </li><li>Research and development expenses: $1,532,362, an increase from $829,815 in the prior year. </li><li>General and administrative expenses: $626,139, a decrease from $1,165,187 in the prior year. </li><li>Sales and marketing expenses: $273,605, a decrease from $483,138 in the prior year. </li><li>Goodwill impairment: $10,857,600, compared to $0 in the prior year. </li></ul></li><li>Nine Months Ended March 31, 2026:<ul><li>Total operating expenses: $17,685,717, significantly up from $7,578,227 in the prior year. </li><li>Research and development expenses: $3,400,149, an increase from $2,610,038 in the prior year. </li><li>General and administrative expenses: $2,449,194, a decrease from $2,947,847 in the prior year. </li><li>Sales and marketing expenses: $901,640, a decrease from $1,606,236 in the prior year. </li><li>Goodwill impairment: $10,857,600, compared to $0 in the prior year. </li></ul></li></ul><h4>Net Loss</h4><ul><li>Three Months Ended March 31, 2026: Net loss was -$12,683,231, compared to -$1,502,202 in the prior year. </li><li>Nine Months Ended March 31, 2026: Net loss was -$14,942,129, compared to -$2,490,522 in the prior year. </li><li>Basic and diluted net loss per share for the nine months ended March 31, 2026, was -$0.71, compared to -$0.13 in the prior year. </li></ul><h4>Adjusted EBITDA Loss</h4><ul><li>Three Months Ended March 31, 2026: Adjusted EBITDA loss was -$1.67 million, compared to -$1.01 million in the prior year. </li><li>Nine Months Ended March 31, 2026: Adjusted EBITDA loss was -$3.50 million, compared to -$1.23 million in the prior year. </li></ul><h4>Cash Flow (Nine Months Ended March 31, 2026)</h4><ul><li>Net cash used in operating activities: -$3,473,924, compared to -$116,534 in the prior year. </li><li>Net cash used in investing activities: -$1,317,249, compared to -$1,541,453 in the prior year. </li><li>Net cash provided by financing activities: $109,768, compared to $6,867,712 in the prior year. </li><li>Net change in cash and cash equivalents: -$4,681,405, compared to $5,209,725 in the prior year. </li><li>Cash and cash equivalents at the end of the period: $2,151,320, compared to $7,058,020 in the prior year. </li></ul><h4>Balance Sheet Highlights (As of March 31, 2026)</h4><ul><li>Cash and cash equivalents: $2,151,320, a decrease from $6,832,725 as of June 30, 2025. </li><li>Total current assets: $3,540,979, down from $8,172,657 as of June 30, 2025. </li><li>Goodwill: $0, down from $10,857,600 as of June 30, 2025, due to impairment. </li><li>Total assets: $3,754,517, a decrease from $19,279,066 as of June 30, 2025. </li><li>Total current liabilities: $1,035,899, down from $2,338,472 as of June 30, 2025. </li><li>Total liabilities: $1,048,270, down from $2,343,176 as of June 30, 2025. </li><li>Accumulated deficit: -$80,534,053, an increase from -$65,591,924 as of June 30, 2025. </li><li>Total stockholders’ equity: $2,706,247, a decrease from $16,935,890 as of June 30, 2025. </li></ul><h4>Capital Infusion</h4><ul><li>A group of investors, including Glimpse’s largest and second largest investors, incoming board members, company co-founders, and executives, invested approximately $1.85 million in common shares and warrants. </li></ul><h4>Outlook / Guidance</h4>The Glimpse Group, Inc. is undergoing a significant strategic shift to become a pureplay Physical AI company, focusing solely on its subsidiary Brightline Interactive, Inc. (BLI). This includes evaluating strategic alternatives for its Immersive tech subsidiary Glimpse Learning and shutting down S5D. The previously announced BLI IPO process has been withdrawn, and Tyler Gates is set to assume the role of CEO, replacing Lyron Bentovim.

Glimpse | 8-K: FY2026 Q3 Revenue Misses Estimate at USD 657.46 K